Home>>Signaling Pathways>> Neuroscience>> Ophthalmology>>15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide

15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide (Synonyms: 15ketoBimatoprost, 17phenyl trinor PGF2α ethyl amide)

Catalog No.GC41937

Bimatoprost is the Allergan trade name for 17-phenyl trinor prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide), an F-series PG analog which has been approved for use as an ocular hypotensive drug.

Products are for research use only. Not for human use. We do not sell to patients.

15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide Chemical Structure

Cas No.: 1163135-96-3

Size Price Stock Qty
1mg
$94.00
In stock
5mg
$425.00
In stock
10mg
$754.00
In stock
25mg
$1,650.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bimatoprost is the Allergan trade name for 17-phenyl trinor prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide), an F-series PG analog which has been approved for use as an ocular hypotensive drug. Oxidation of the C-15 hydroxyl group produces 15-keto-17-phenyl trinor PGF2α ethyl amide. 15-keto-17-phenyl trinor PGF2α ethyl amide is a potential metabolite of 17-phenyl trinor PGF2α ethyl amide when 17-phenyl trinor PGF2α ethyl amide is administered to intact animals. No pharmacological studies on 15-keto-17-phenyl trinor PGF2α ethyl amide have been reported.

Reviews

Review for 15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.